Skip to content
HCN Grants Est. 2026
No. PAR-25-296 · National Institutes of Health
Open

Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)

Dealbreakers No cost share required Audit: not stated
Not reimbursement-only
“Cooperative Agreement: A financial assistance mechanism used when there will be substantial Federal scientific or programmatic involvement.” — From the announcement

At a glance

This program funds collaborative projects that develop, demonstrate, and spread innovative solutions to speed translational research across the CTSA Program and beyond. Eligible applicants include CTSA Program hubs and CTSA partnering institutions, and applications must fit the research interests of at least one participating NIH Institute, Center, or Office. The announcement does not state the number or size of awards or any cost-share requirement. Some topics have special scope limits, including NHGRI support for genomics tools for clinical trials, NIAID support for preclinical chemical countermeasure research only, and NIH institute-specific interests such as FDA regulatory science, NCATS data science and clinical trial innovation, and NIAMS disease-related translation.

AI-generated summary — verify against the announcement

What it funds

  • Health
  • Income Security and Social Services
  • Research & Discovery
  • Researchers & Scholars
  • Biomedical & Disease Research
  • Research Infrastructure, Instrumentation & Data
Official description from grants.gov

The CTSA Collaborative and Innovative Acceleration Award (CCIA) aims to accelerate the pace of translational research by supporting the collaborative development, dissemination, and sustainable implementation of innovative solutions across the CTSA Program Consortium and beyond. This Notice of Funding Opportunity (NOFO) invites investigator-initiated applications to develop, demonstrate, and disseminate innovative new approaches, technologies, resources, or models that increase the impact of research across diseases, transform the field of translational science, and bring more treatments for all people more quickly.

Who can apply

  • Public and State controlled institutions of higher education
Geographic restriction None found in the announcement — likely nationwide